HC Wainwright & Co. Reaffirms Buy Rating for LifeMD, Adjusts Price Target to $9
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2025
0mins
Should l Buy LFMD?
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFMD
Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.800
Low
6.00
Averages
9.67
High
15.00
Current: 2.800
Low
6.00
Averages
9.67
High
15.00
About LFMD
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LifeMD Executives Allegedly Breached Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether LifeMD, Inc. executives breached their fiduciary duties to shareholders, with potential legal risks that could undermine shareholder confidence.
- Overstated Competitive Position: A federal securities lawsuit claims that LifeMD's competitive position was materially overstated, which may distort investor expectations regarding the company's future and impact shareholder investment decisions.
- Improper Financial Guidance: LifeMD's decision to raise its 2025 guidance is criticized as reckless due to the failure to adequately account for rising customer acquisition costs in its RexMD segment, potentially leading to poor future financial performance.
- Lack of Disclosure: The company failed to disclose customer acquisition costs related to the sale of obesity drugs, resulting in materially false and misleading statements about LifeMD's business, operations, and prospects, which could trigger shareholder lawsuits.
See More
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
See More
Novo Nordisk Launches Wegovy Pill with 17% Average Weight Loss Efficacy
- Significant Weight Loss Efficacy: The Wegovy pill demonstrates an average weight loss of approximately 17% (16.6%) when combined with a reduced-calorie diet and exercise, compared to only 3% (2.7%) for the placebo, indicating strong market potential that could drive Novo Nordisk's sales growth.
- Diverse Purchasing Channels: Wegovy is available through various outlets, including CVS and Costco, with a starting dose of 1.5 mg priced at around $149 per month, ensuring patient accessibility and expanding market coverage.
- Price Strategy Adjustment: Novo Nordisk has halved Wegovy prices in China ahead of impending generic competition, a strategy that not only enhances market competitiveness but may also attract more consumers to choose its products.
- Stock Performance Recovery: Novo Nordisk shares rose 4.14% to $54.55, although still trading 8.4% below the 200-day SMA, the recent strong performance may attract more investor interest and boost market confidence.
See More
LifeMD Expands Collaboration with Novo Nordisk to Enhance Offerings
- Collaboration Expansion: LifeMD announced an expansion of its collaboration with Novo Nordisk, aimed at enhancing service capabilities in health management, although specific financial terms remain undisclosed, this move could strengthen LifeMD's competitive position in the market.
- Market Potential: This partnership will enable LifeMD to leverage Novo Nordisk's expertise and resources, further expanding its market share in chronic disease management and health technology, which is expected to positively impact future revenue growth.
- Strategic Significance: By collaborating with Novo Nordisk, LifeMD not only enhances the diversity of its product offerings but also attracts more customers through Novo Nordisk's brand influence, thereby increasing customer loyalty.
- Future Outlook: The expansion of this collaboration signifies LifeMD's ongoing investment in the health technology sector, indicating the company's commitment to driving long-term growth and innovation through strategic partnerships.
See More
LifeMD Launches Wegovy for Weight Management at $149/month
- New Drug Launch: LifeMD introduces Novo Nordisk's Wegovy through its telehealth platform at an accessible price of $149 per month, significantly expanding its portfolio of branded obesity treatments and enhancing its competitive position in the market.
- Strengthened Collaboration: This launch deepens LifeMD's partnership with Novo Nordisk, as the company is now featured as a trusted telehealth provider on the NovoCare and Wegovy websites, thereby increasing brand credibility and trust among patients.
- FDA Approval: Wegovy received FDA approval on December 22, 2025, as the first oral GLP-1 therapy aimed at reducing excess body weight and lowering the risk of certain major cardiovascular events, aligning with growing market demand for effective weight management solutions.
- Stock Price Reaction: Following the announcement, LifeMD's shares rose over 3% in pre-market trading, closing at $3.49, indicating positive market expectations and increased investor confidence in the company's new product offering.
See More
LifeMD Launches Wegovy Oral Medication at $149 Monthly Fee
- New Drug Launch: LifeMD introduces Novo Nordisk's Wegovy oral medication through its telehealth platform at an attractive monthly fee of $149, further expanding its portfolio of branded obesity treatments and likely attracting more patients seeking convenient healthcare services.
- FDA Approval: The Wegovy oral medication is the first FDA-approved oral GLP-1 therapy, demonstrating an average weight loss of 16.6% in a 64-week clinical trial, significantly outperforming the 2.7% reduction seen with placebo, which is expected to enhance LifeMD's market share in obesity management.
- Strengthened Partnership: LifeMD's long-standing collaboration with Novo Nordisk is reinforced as LifeMD is featured as a trusted telehealth provider on the NovoCare and Wegovy websites, reflecting the growing demand for branded GLP-1 therapies.
- Enhanced Patient Experience: By integrating with NovoCare Pharmacy, LifeMD offers a comprehensive healthcare experience that includes virtual visits, rapid medication delivery, and real-time tracking, which is anticipated to improve patient satisfaction and foster long-term customer loyalty.
See More
LifeMD Executives Allegedly Breached Fiduciary Duties
- Fiduciary Duty Investigation: Kuehn Law, PLLC is investigating whether LifeMD, Inc. executives breached their fiduciary duties to shareholders, with potential legal risks that could undermine shareholder confidence.
- Overstated Competitive Position: A federal securities lawsuit claims that LifeMD's competitive position was materially overstated, which may distort investor expectations regarding the company's future and impact shareholder investment decisions.
- Improper Financial Guidance: LifeMD's decision to raise its 2025 guidance is criticized as reckless due to the failure to adequately account for rising customer acquisition costs in its RexMD segment, potentially leading to poor future financial performance.
- Lack of Disclosure: The company failed to disclose customer acquisition costs related to the sale of obesity drugs, resulting in materially false and misleading statements about LifeMD's business, operations, and prospects, which could trigger shareholder lawsuits.
See More
Zentalis Pharmaceuticals (ZNTL) Surges 17.65% as Investors Renew Interest
- Zentalis Pharmaceuticals Surge: Zentalis Pharmaceuticals' stock rose 17.65% to $4.40 in after-hours trading, with no new news but bolstered by a corporate update on January 6, 2026, highlighting key milestones in its azenosertib development program, which has renewed investor confidence in its pipeline progress.
- LifeMD Secures Financing: LifeMD's stock climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability, with $30 million committed, which is expected to support the company's organic growth initiatives.
- NanoViricides Attracts Speculative Interest: NanoViricides' stock advanced 11.11% to $1.24, drawing speculative interest in after-hours trading despite no new announcements, indicating ongoing market enthusiasm for biotech companies.
- Neurogene Participates in Healthcare Conference: Neurogene's stock increased 2.06% to $18.29 as the management team prepares to present at the 44th Annual J.P. Morgan Healthcare Conference, enhancing market expectations for its future developments.
See More
Novo Nordisk Launches Wegovy Pill with 17% Average Weight Loss Efficacy
- Significant Weight Loss Efficacy: The Wegovy pill demonstrates an average weight loss of approximately 17% (16.6%) when combined with a reduced-calorie diet and exercise, compared to only 3% (2.7%) for the placebo, indicating strong market potential that could drive Novo Nordisk's sales growth.
- Diverse Purchasing Channels: Wegovy is available through various outlets, including CVS and Costco, with a starting dose of 1.5 mg priced at around $149 per month, ensuring patient accessibility and expanding market coverage.
- Price Strategy Adjustment: Novo Nordisk has halved Wegovy prices in China ahead of impending generic competition, a strategy that not only enhances market competitiveness but may also attract more consumers to choose its products.
- Stock Performance Recovery: Novo Nordisk shares rose 4.14% to $54.55, although still trading 8.4% below the 200-day SMA, the recent strong performance may attract more investor interest and boost market confidence.
See More
LifeMD Expands Collaboration with Novo Nordisk to Enhance Offerings
- Collaboration Expansion: LifeMD announced an expansion of its collaboration with Novo Nordisk, aimed at enhancing service capabilities in health management, although specific financial terms remain undisclosed, this move could strengthen LifeMD's competitive position in the market.
- Market Potential: This partnership will enable LifeMD to leverage Novo Nordisk's expertise and resources, further expanding its market share in chronic disease management and health technology, which is expected to positively impact future revenue growth.
- Strategic Significance: By collaborating with Novo Nordisk, LifeMD not only enhances the diversity of its product offerings but also attracts more customers through Novo Nordisk's brand influence, thereby increasing customer loyalty.
- Future Outlook: The expansion of this collaboration signifies LifeMD's ongoing investment in the health technology sector, indicating the company's commitment to driving long-term growth and innovation through strategic partnerships.
See More
LifeMD Launches Wegovy for Weight Management at $149/month
- New Drug Launch: LifeMD introduces Novo Nordisk's Wegovy through its telehealth platform at an accessible price of $149 per month, significantly expanding its portfolio of branded obesity treatments and enhancing its competitive position in the market.
- Strengthened Collaboration: This launch deepens LifeMD's partnership with Novo Nordisk, as the company is now featured as a trusted telehealth provider on the NovoCare and Wegovy websites, thereby increasing brand credibility and trust among patients.
- FDA Approval: Wegovy received FDA approval on December 22, 2025, as the first oral GLP-1 therapy aimed at reducing excess body weight and lowering the risk of certain major cardiovascular events, aligning with growing market demand for effective weight management solutions.
- Stock Price Reaction: Following the announcement, LifeMD's shares rose over 3% in pre-market trading, closing at $3.49, indicating positive market expectations and increased investor confidence in the company's new product offering.
See More
LifeMD Launches Wegovy Oral Medication at $149 Monthly Fee
- New Drug Launch: LifeMD introduces Novo Nordisk's Wegovy oral medication through its telehealth platform at an attractive monthly fee of $149, further expanding its portfolio of branded obesity treatments and likely attracting more patients seeking convenient healthcare services.
- FDA Approval: The Wegovy oral medication is the first FDA-approved oral GLP-1 therapy, demonstrating an average weight loss of 16.6% in a 64-week clinical trial, significantly outperforming the 2.7% reduction seen with placebo, which is expected to enhance LifeMD's market share in obesity management.
- Strengthened Partnership: LifeMD's long-standing collaboration with Novo Nordisk is reinforced as LifeMD is featured as a trusted telehealth provider on the NovoCare and Wegovy websites, reflecting the growing demand for branded GLP-1 therapies.
- Enhanced Patient Experience: By integrating with NovoCare Pharmacy, LifeMD offers a comprehensive healthcare experience that includes virtual visits, rapid medication delivery, and real-time tracking, which is anticipated to improve patient satisfaction and foster long-term customer loyalty.
See More
